New drug duo aims to outperform standard pill for common lung cancer

NCT ID NCT06838273

Recruiting now Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial is testing whether adding an experimental IV drug called BL-B01D1 to the standard pill osimertinib works better than osimertinib alone for people with advanced EGFR-mutated non-small cell lung cancer. About 720 participants will be randomly assigned to one of the two treatment groups. The main goal is to see if the combination delays cancer growth longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BL-B01D1 (a drug given by IV) combined with osimertinib (a daily pill)
What this could lead to: If successful, this combination could become a new first-line treatment option that delays cancer progression longer than osimertinib alone for people with EGFR-mutated lung cancer.
What could go wrong: This is an early-phase 3 trial, so results are not yet known. The combination may cause more side effects than osimertinib alone, and it might not improve survival or quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Shanghai East Hospital
RECRUITING

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.